Showing results (1-10 of 68) with videos related to
Sort By:
Pageof 7
Therapeutic Advances in Drug Safety|August 2, 2014
Safety of dipeptidyl peptidase 4 inhibitors: a perspective reviewThomas Karagiannis, Panagiota Boura, Apostolos TsapasAnnals of Internal Medicine|January 1, 2024
In T2DM requiring insulin initiation, icodec titrated with an app safely reduced HbA1c vs. daily basal insulin analogues at 52 wkAris Liakos, Thomas Karagiannis, Apostolos TsapasDiabetologia|July 11, 2023
Socioeconomic aspects of incretin-based therapyThomas Karagiannis, Eleni Bekiari, Apostolos TsapasAnnals of Internal Medicine|May 4, 2026
In adults with T2D and ASCVD, tirzepatide was noninferior to dulaglutide for a composite CV outcome at a median 4 yThomas Karagiannis, Ioannis Avgerinos, Apostolos Tsapas, et al.Core Evidence|March 30, 2017
Canagliflozin in the treatment of type 2 diabetes: an evidence-based review of its place in therapyThomas Karagiannis, Eleni Bekiari, Apostolos TsapasAnnals of Internal Medicine|March 1, 2021
KDIGO made 12 recommendations for managing diabetes with CKDThomas Karagiannis, Apostolos Tsapas, Eleni BekiariDiabetes Research and Clinical Practice|November 9, 2022
Efficacy and safety of ultra-rapid insulin analogues in insulin pumps in patients with Type 1 Diabetes Mellitus: A systematic review and meta-analysisAthina Stamati, Thomas Karagiannis, Apostolos Tsapas, et al.Current Diabetes Reports|January 13, 2026
SGLT-2 Inhibitors and GLP-1 Receptor Agonists as Combination Therapy in Type 2 DiabetesAris Liakos, Thomas Karagiannis, Ioannis Avgerinos, et al.Diabetes Research and Clinical Practice|June 18, 2021
GLP-1 receptor agonists for cardiovascular outcomes with and without metformin. A systematic review and meta-analysis of cardiovascular outcomes trialsApostolos Tsapas, Thomas Karagiannis, Ioannis Avgerinos, et al.Expert Opinion on Drug Discovery|April 24, 2024
The preclinical discovery and clinical evaluation of tirzepatide for the treatment of type 2 diabetesIoannis Avgerinos, Panagiota Kakotrichi, Thomas Karagiannis, et al.Pageof 7